News & Updates

Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.

The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.

Treatment with semaglutide helps reduce kidney fat and enhance glomerular haemodynamic in adult patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the REMODEL trial.

Multimodality focal therapy shortens operation time and hospitalization, and reduces complications in patients with localized prostate cancer, according to researchers from the Chinese University of Hong Kong (CUHK).

Researchers from the University of Hong Kong (HKU) have identified enrichment in Phocaeicola vulgatus as a potential cause for immunotherapy (IO) resistance in patients with hepatocellular carcinoma (HCC) and shown Sthat supplementation with indoleacetic acid (IAA) can overcome P. vulgatus–induced immunosuppression, thereby establishing a causal relationship between P. vulgatus and anti–PD-1 resistance in HCC.

A single-institution retrospective study comparing proton therapy with conventional radiotherapy using tomotherapy or volumetric modulated arc therapy demonstrated low toxicity and significant dosimetric advantage with proton therapy in Chinese breast cancer patients following definitive surgery, according to data presented at APTCOG-AO 2025 conference held in Hong Kong.